Cite

HARVARD Citation

    Long, G. et al. (2018). Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Annals of oncology. pp. 2208-2213. [Online]. 
  
Back to record